Aclarion, Inc.

Aclarion, Inc. is a healthcare technology company dedicated to advancing the care of patients suffering from chronic lower back pain. The company's mission is to deliver noninvasive, evidence-based, SaaS solutions that empower physicians to create personalized treatment plans, aiming to improve clinical outcomes and help patients return to a life free from back pain. Headquartered in Broomfield, Colorado, Aclarion operates at the intersection of medical imaging and artificial intelligence.

The company's flagship product is NOCISCAN, a proprietary Software-as-a-Service (SaaS) platform. NOCISCAN leverages Magnetic Resonance Spectroscopy (MRS) capabilities of existing MRI scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. Through proprietary signal-processing biomarkers and augmented intelligence (AI) algorithms, NOCISCAN identifies chemical biomarkers associated with degenerative pain and structural integrity of lumbar discs. The platform includes NOCICALC, a Class I medical device for post-processing raw MRS data, and NOCIGRAM, which processes results into individualized NOCISCORES to indicate potential sources of pain.

Led by CEO Brent Ness, who was appointed in September 2021, Aclarion has recently reported strong Q1 2026 results, demonstrating 196% annual scan volume growth. The company secured a U.S. Patent (#12,601,803) in April 2026 for its AI-driven MRS data analysis platform, expanding its intellectual property portfolio. Aclarion also announced a $2.5 million stock repurchase plan and an agreement with Weill Cornell Medicine in April 2026. The ongoing CLARITY trial, a pivotal multi-site randomized study, is expected to provide initial readouts in Q4 2026, further solidifying NOCISCAN's market positioning as a leading non-invasive diagnostic tool for chronic low back pain.